Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30034011 | 1.00 | KDM1A (0.39) | KDM1AMAOBDPP4ALDH1A1HPGD | |
| SCHEMBL31294217 | 0.81 | KMT2A (0.38) | KDM1AMAOBDPP4LMNASMN1; SMN2 | |
| SCHEMBL3668845 | 0.78 | ALDH1A1 (0.39) | DPP4ALDH1A1HPGDMAPTKDM4E | |
| SCHEMBL22904480 | 0.77 | KMT2A (0.35) | ALDH1A1HPGDLMNASMN1; SMN2MAPT | |
| SCHEMBL11940515 | 0.77 | ALDH1A1 (0.36) | DPP4ALDH1A1HPGDMAPTKDM4E | |
| SCHEMBL20244713 | 0.76 | CYP11B2 (0.41) | KDM1ADPP4ALDH1A1HPGDMAPT | |
| SCHEMBL1543531 | 0.76 | CYP11B1 (0.53) | ALDH1A1HPGDLMNAMAPTKDM4E | |
| SCHEMBL3596542 | 0.76 | ALDH1A1 (0.38) | ALDH1A1HPGDMAPTCYP11B1KMT2A | |
| SCHEMBL533904 | 0.76 | CYP11B1 (0.45) | DPP4ALDH1A1HPGDCASP3SENP8 | |
| SCHEMBL31565019 | 0.76 | BACE1 (0.42) | KDM1AMAOBDPP4ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFLECTION THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4547246-A2 | COMPOUNDS AS INHIBITORS OF AXL | Arcus Biosciences, Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-115925622-B | Synthesis method of 3-cyanopyridine-2-yl tert-butyl carbamate | 山西永津集团有限公司 | 2025-04-22 | — | — | CN | disclosed |
| CN-119365453-A | Compounds as AXL inhibitors | 艾库斯生物科学有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-222384797-U | Device for producing 2-chloronicotinonitrile by continuous chlorination reaction of cyanopyridine nitrogen oxide | 广西新天德能源有限公司 | 2025-01-24 | — | — | CN | disclosed |
| US-12195482-B1 | Compounds as inhibitors of AXL | ARCUS BIOSCIENCES, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| US-20240425526-A1 | COMPOUNDS AS INHIBITORS OF AXL | ARCUS BIOSCIENCES, INC. (US) | 2024-12-26 | — | — | US | disclosed |
| CN-119120435-A | Nitrilase mutant capable of reducing selectivity of 5-chloronicotinonitrile and improving selectivity of 6-chloronicotinonitrile and application thereof | 浙江工业大学 | 2024-12-13 | — | — | CN | disclosed |
| CN-118240807-A | Nitrilase mutant with improved heat stability and application thereof in synthesis of 2-chloronicotinic acid | 浙江工业大学 | 2024-06-25 | — | — | CN | disclosed |
| CN-118185909-A | Nitrilase mutant and application thereof in improving yield of 2-chloronicotinic acid | 浙江工业大学 | 2024-06-14 | — | — | CN | disclosed |
| WO-2005016913-A1 | TETRAHYDROISOQUINOLINE OR ISOCHROMAN COMPOUNDS AS ORL-1 RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN AND CNS DISORDERS | PFIZER JAPAN, INC. (JP) | 2005-02-24 | — | — | WO | disclosed |
| US-20040063942-A1 | Spiro-indolines as Y5 receptor antagonists | MERCK & CO., INC. | 2004-04-01 | — | — | US | disclosed |
| US-6638942-B1 | Useful in the treatment of obesity and the complications associated therewith. | MERCK & CO., INC. | 2003-10-28 | — | — | US | disclosed |
| EP-1129089-A4 | SPIRO-INDOLINES AS Y5 RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2003-01-22 | — | — | EP | disclosed |
| US-6495559-B2 | FOR THERAPY OF OBESITY | MERCK & CO., INC. | 2002-12-17 | — | — | US | disclosed |
| US-20020058813-A1 | Spiro-indolines as Y5 receptor antagonists | MSD K.K. (JP) | 2002-05-16 | — | — | US | disclosed |
| US-6313298-B1 | OBESITY, DIETETICS; NEUROPEPTIDE Y ANTAGONISTS | MERCK & CO., INC. | 2001-11-06 | — | — | US | disclosed |
| EP-1129089-A1 | SPIRO-INDOLINES AS Y5 RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2001-09-05 | — | — | EP | disclosed |
| US-6191160-B1 | DIETETICS | MERCK & CO., INC. | 2001-02-20 | — | — | US | disclosed |
| WO-2000027845-A1 | SPIRO-INDOLINES AS Y5 RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12195482-B1 | Compounds as inhibitors of AXL | AXL, FLT3, BTK | KDM1A 2790/4885MAOB 2507/4885DPP4 2177/4885 |
| US-20040063942-A1 | Spiro-indolines as Y5 receptor antagonists | NPY5R, NPY1R, NPY2R | KDM1A 2685/4885MAOB 307/4885DPP4 822/4885 |
| US-20020058813-A1 | Spiro-indolines as Y5 receptor antagonists | NPY5R, NPY1R, NPY2R | KDM1A 2698/4885MAOB 302/4885DPP4 814/4885 |
| US-20240425526-A1 | COMPOUNDS AS INHIBITORS OF AXL | AXL, FLT3, BTK | KDM1A 2790/4885MAOB 2507/4885DPP4 2177/4885 |
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | SUB1, AHR, NCOA3 | KDM1A 1380/4885MAOB 1041/4885DPP4 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.